City of Hope

Clinical research site in Duarte, California · 1500 DUARTE RD, DUARTE, CA 91010-3012 · (626) 256-4673 · Website

Part of City of Hope

As of July 2026, 438 paid clinical trials are recruiting at City of Hope in Duarte, California. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at City of Hope (438)

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

for Urothelial Cancer

74 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07421700·Phase 1, Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

for Adenovirus Infections

26 locations incl. Phoenix

Sponsor: SymBio Pharmaceuticals

Sex: All·Age: 2 Months+

Code: NCT07387367·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

for Carcinoma, Renal Cell

109 locations incl. Phoenix

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227415·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

29 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07266441·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

34 locations incl. Goodyear

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT07213674·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for Ovarian Neoplasms

88 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for Ovarian Cancer

38 locations incl. Anchorage

Sponsor: Incyte Corporation

Sex: Female·Age: 18+

Code: NCT07214779·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

for Early Breast Cancer

85 locations incl. Birmingham

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for Lymphoma, Large B-Cell, Diffuse

71 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

52 locations incl. Gilbert

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

134 locations incl. Daphne

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

77 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

37 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

for Urinary Bladder Neoplasms

41 locations incl. Tucson

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05614739·Phase 1·Recruiting·Listed Nov 2022

Apply to this trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

for Leukemia, Myeloid, Acute

51 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

for Metastatic Colorectal Cancer

19 locations incl. Phoenix

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT04929223·Phase 1·Recruiting·Listed Jun 2021

Apply to this trial

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

for Multiple Myeloma

28 locations incl. Phoenix

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05201781·Phase 4·Recruiting·Listed Jan 2022

Apply to this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

66 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for Prostate Cancer

49 locations incl. Phoenix

Sponsor: Merck Sharp & Dohme LLC

Sex: Male·Age: 18+

Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of ASP3082 in Adults With Advanced Solid Tumors

for Solid Tumor

24 locations incl. Duarte

Sponsor: Astellas Pharma Inc

Sex: All·Age: 18+

Code: NCT05382559·Phase 1·Recruiting·Listed May 2022

Apply to this trial

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

for Pancreatic Ductal Adenocarcinoma

25 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06586515·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

for Non-Small Cell Lung Cancer, NSCLC

28 locations incl. Gilbert

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06162221·Phase 1, Phase 2·Recruiting·Listed Dec 2023

Apply to this trial

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

for Advanced Breast Cancer

37 locations incl. Springdale

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06638307·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for Non Small Cell Lung Cancer

10 locations incl. Duarte

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT04928846·Phase 3·Recruiting·Listed Jun 2021

Apply to this trial

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

for Endometrial Adenocarcinoma

42 locations incl. Phoenix

Sponsor: Acrivon Therapeutics

Sex: Female·Age: 18+

Code: NCT05548296·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

for Melanoma, Cutaneous Malignant

37 locations incl. Phoenix

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT06743126·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

for Acute Leukemia

23 locations incl. Duarte

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 2+

Code: NCT04811560·Phase 1, Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

for Carcinoma, Squamous Cell

22 locations incl. Birmingham

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 60+

Code: NCT04892173·Phase 3·Recruiting·Listed May 2021

Apply to this trial

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

for Head and Neck Squamous Cell Carcinoma

29 locations incl. Duarte

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT06163534·Recruiting·Listed Dec 2023

Apply to this trial

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

for Prostate Cancer

23 locations incl. Duarte

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT04221542·Phase 1·Recruiting·Listed Jan 2020

Apply to this trial

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

for Platinum-resistant Ovarian Cancer

32 locations incl. Mobile

Sponsor: Genelux Corporation

Sex: Female·Age: 18+

Code: NCT05281471·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

for Follicular Lymphoma

31 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: 18+

Code: NCT06911502·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for Myelofibrosis

30 locations incl. Birmingham

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 18+

Code: NCT04176198·Phase 1, Phase 2·Recruiting·Listed Nov 2019

Apply to this trial

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

for Relapsed Hematologic Malignancy

18 locations incl. Phoenix

Sponsor: Curis, Inc.

Sex: All·Age: 18+

Code: NCT03328078·Phase 1, Phase 2·Recruiting·Listed Nov 2017

Apply to this trial

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

for Myelodysplastic Syndrome

42 locations incl. Duarte

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04227847·Phase 1·Recruiting·Listed Jan 2020

Apply to this trial

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

for cGVHD

31 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05919511·Recruiting·Listed Jun 2023

Apply to this trial

Showing the 40 most relevant of 438 recruiting trials at this site. Browse all with filters →

More research sites in Duarte

City of Hope Medical Center (172 trials)
City of Hope Comprehensive Cancer Center (80 trials)
City of Hope National Medical Center (50 trials)
City of Hope (City of Hope National Medical Center, City of Hope Medical Center) (9 trials)
City of Hope - Duarte Cancer Center (6 trials)
City of Hope Cancer Center (6 trials)
City of Hope - Duarte (4 trials)
City of Hope Cancer Center (Data collection only) (3 trials)
Beckman Research Institute of City of Hope (2 trials)
City of Hope Duarte (2 trials)

Explore more

Paid clinical trials in Duarte, CA · California clinical trials